ArticleOncoTargets and therapy2010
Anti-angiogenesis therapies: their potential in cancer management.
Article in OncoTargets and therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 69 citations in OpenAlex.
- A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.BMC medicine · 2022Trial
- Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits.Nature genetics · 2024Article
- Circulating VEGF and inflammatory bowel disease: a bidirectional mendelian randomization.Frontiers in genetics · 2024Article
- Circulating vascular endothelial growth factor and cancer risk: A bidirectional mendelian randomization.Frontiers in genetics · 2022Article
- The effect of interleukin-17F on vasculogenic mimicry in oral tongue squamous cell carcinoma.Cancer science · 2021Article
- Antiangiogenic effects of oridonin.BMC complementary and alternative medicine · 2017Article
- Current targeted therapies in the treatment of advanced colorectal cancer: a review.Therapeutic advances in medical oncology · 2016Review
- Basic fibroblast growth factor shows prognostic impact on survival in operable non-small cell lung cancer patients.Thoracic cancer · 2015Article
- Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome.Clinical case reports · 2015Article
- Lung cancer cellular apoptosis induced by recombinant human endostatin gold nanoshell-mediated near-infrared thermal therapy.International journal of clinical and experimental medicine · 2015Article
- Neuropilin-1 as Therapeutic Target for Malignant Melanoma.Frontiers in oncology · 2015Review
- Radioembolization of hepatic tumors.Journal of gastrointestinal oncology · 2014Review
- Cancer biology in diabetes.Journal of diabetes investigation · 2014Review
- Suppression of angiogenesis and tumor growthExperimental and therapeutic medicine · 2014Article
- Solution structure of the major G-quadruplex formed in the human VEGF promoter in K+: insights into loop interactions of the parallel G-quadruplexes.Nucleic acids research · 2013Article
- Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice.Experimental and therapeutic medicine · 2013Article
- RNA interference-mediated silencing of VEGF and bFGF suppresses endostatin secretion in pancreatic carcinoma cells.Oncology letters · 2013Article
- 1-aryl-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as VEGFR-2 tyrosine kinase inhibitors: synthesis, biological evaluation, and molecular modelling studies.BioMed research international · 2013Article
- Unique biology of gliomas: challenges and opportunities.Trends in neurosciences · 2012Review
- Diabetic angiopathy and angiogenic defects.Fibrogenesis & tissue repair · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis plays an important role in normal animal growth and development. This process is also vital for the growth of tumors. Angiogenesis inhibitors have a different mechanism of action to traditional chemotherapy agents and radiation therapy. The angiogenesis inhibitors can act synergistically with conventional treatments and tend to have non-overlapping toxicities. There are four drugs which have a proven role in treating cancer patients. Bevacizumab is a humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF). Sunitinib and sorafenib inhibit multiple tyrosine kinase receptors that are important for angiogenesis. Thalidomide inhibits the activity of basic fibroblast growth factor-2 (bFGF). The licensed indications and the supporting evidence are discussed. Other drugs are currently being tested in clinical trials and the most promising of these drugs are discussed. Aflibercept, also known as VEGF-trap, is a recombinant fusion protein that binds to circulating VEGF. The vascular disrupting agents act by targeting established blood vessels. These exciting new treatments have the potential to transform the management of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.